Hyperion Therapeutics Inc. (HPTX) reported a fourth-quarter net loss of $8.3 million or $0.50 per share, compared to a net loss of $8.7 million or $18.44 per share in the year ago quarter.
Weighted average number of shares used to compute net loss per share of common stock surged to 16.61 million from 469,319 last year.
Research and development expenses for the fourth quarter 2012 were $3.0 million compared with $3.5 million for the same period in 2011. The decrease for the quarter was primarily due to reduced clinical development and consulting expenses related to the company's HE Phase II trial and the long-term safety extension trial in adults with UCD both of which were largely completed in 2011.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.